Adaptive Biotechnologies Corp
Research Adaptive Biotechnologies Corp (ADPT) on Bullrun: market cap USD 4.18B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADPT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 4.18B
- Financial periodQ1 2026
- RevenueUSD 70.87M
- Net income-USD 49.68M
- Free cash flow-USD 10.33M
- Gross margin313.7%
Valuation Snapshot
latest market cap is USD 4.18B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 276.98M | -USD 59.50M | -USD 48.95M | 74.2% | -0.39 | USD 70.50M | USD 131.21M | USD 218.79M |
| FY2024 | USD 178.96M | -USD 159.49M | -USD 98.88M | 59.7% | -1.08 | USD 47.92M | USD 133.28M | USD 202.71M |
| FY2023 | USD 170.28M | -USD 225.25M | -USD 167.02M | 55.6% | -1.56 | USD 65.06M | USD 130.66M | USD 308.40M |
| FY2022 | USD 185.31M | -USD 200.19M | -USD 200.29M | 68.7% | -1.4 | USD 90.03M | USD 125.36M | USD 464.17M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.18B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.50B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 885.16M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 709.39M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.09B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.97B | n/a | n/a | n/a |
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adaptive Biotechnologies Corp's market cap?
Adaptive Biotechnologies Corp's market capitalization is USD 4.18B.
What does Adaptive Biotechnologies Corp do?
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).